01 Expansion of Immunotherapy Into Earlier Lines of Cancer Treatment Immunotherapy drugs are increasingly being incorporated into treatment settings that occur earlier in the cancer-care pathway rather than being reserved primarily for advanced or previously treated disease. This shift is increasing the eligible patient population and allowing immune-based therapies to be used alongside surgery, chemotherapy, or radiation. Earlier intervention is therefore broadening the clinical role of immunotherapy across multiple tumor types. In June 2025, the U.S. Food and Drug Administration approved pembrolizumab as neoadjuvant and adjuvant treatment for resectable locally advanced head and neck squamous cell carcinoma, marking its first perioperative approval in this disease.
02 Increasing Development of Alternative Immunotherapy Delivery Methods Immunotherapy development is increasingly focused not only on new drug targets but also on improving how established therapies are administered. Subcutaneous formulations can potentially shorten administration time and reduce the burden associated with intravenous infusions while maintaining access to established immune-based treatments. This is encouraging drug developers to pursue more convenient delivery formats. In September 2025, the U.S. Food and Drug Administration approved a subcutaneous formulation of pembrolizumab and berahyaluronidase alfa for the same solid-tumor indications covered by intravenous pembrolizumab.
01 Increasing Cancer Incidence Expands the Addressable Treatment Population The growing global burden of cancer is increasing the number of patients requiring systemic therapies, including immune-based treatments. Continued expansion of oncology treatment demand therefore supports the underlying market.
01 High Treatment Costs Can Limit Access to Immunotherapy Many immunotherapy drugs involve complex development, manufacturing, administration, and monitoring requirements, which can result in high treatment costs. The financial burden may be particularly restrictive where reimbursement coverage is limited or healthcare budgets are constrained. Cost considerations can therefore affect patient access and the speed at which newer immunotherapies are incorporated into treatment systems.
01 Expansion of Biomarker-Guided Immunotherapy Biomarker testing is creating opportunities to identify patients who are more likely to benefit from specific immunotherapy drugs. Greater integration of companion diagnostics with immunotherapy development can therefore support more targeted treatment strategies.
01 Managing Serious Immune-Mediated Adverse Reactions Immune-based therapies can activate the immune system strongly enough to cause inflammatory effects in healthy tissues. Managing these reactions while preserving anticancer activity remains a major clinical challenge.
March 2026 Merck & Co. expanded its immuno-oncology portfolio with continued clinical development and commercialization initiatives for Keytruda® (pembrolizumab), strengthening its role in cancer immunotherapy treatments.
September 2025 Bristol Myers Squibb advanced its immunotherapy pipeline through new clinical programs and combination therapy developments aimed at improving treatment outcomes across multiple cancer indications.
May 2025 Roche expanded its oncology immunotherapy portfolio with new research and development initiatives focused on personalized cancer treatment approaches and immune-based therapies.